Company profile
Myomo, Inc.
AMEX: MYO · Healthcare · Medical - Devices
#463 of 1,418 Healthcare companies by revenue70th-percentile growth
EA Score
53DFH 48DQ 61GM 51SS 60
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, workforce scale · ↓ growth stability, return on equity
Methodology →Revenue TTM
$41.2M
Rev growth YoY (TTM)
+6.7%
Net income (FY)
-$15.6M
Employees
195
as of 2026-08-20
Market cap
$71.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$40.9M$40.9M2025
Net income-$15.6M-$15.6M2025
Operating income-$14.4M-$14.4M2025
Total assets$38.6M$38.6M2025
Liabilities$27.2M$27.2M2025
Equity$11.4M$11.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Product100%
By geography
Not disclosed.
The read
What is Myomo, Inc.’s revenue?
Myomo, Inc. booked $40.9M in FY2025 revenue, growing 26% year over year — faster than most Healthcare companies we track, at a -38.1% net margin.
Peers · Healthcare
KORU Medical Systems, Inc.72BFilana Therapeutics, Inc.42DEquillium, Inc.44DEditas Medicine, Inc.45DAlpha Teknova, Inc.58CVoyager Therapeutics, Inc.53DNeighbors
Middlesex →Key facts
CEOPaul R. Gudonis
SectorHealthcare
IndustryMedical - Devices
HeadquartersBurlington, MA
ExchangeAMEX: MYO
Employees195
IPO date2017-06-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.